{"transactions":[{"id":725474,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:16.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001575408-26-000002","document":"form4-06262026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000157540826000002/form4-06262026_040610.xml","form_type":"4"}},{"id":1094317,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":109329,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":43,"underlying":"Common Stock","underlying_shares":109329},"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1094316,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":38.4,"underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1094315,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":260000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":27.64,"underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1094314,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":325000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":33.66,"underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1094313,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":176411,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":2.3,"underlying":"Common Stock","underlying_shares":176411},"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1094312,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":769804,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":2.3,"underlying":"Common Stock","underlying_shares":769804},"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1094311,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22760,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each vested outstanding option to purchase shares of Issuer common stock immediately prior to the Effective Time, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time. Each unvested option outstanding was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the total number of shares of (Continued in footnote 8)"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Issuer common stock subject to such option immediately prior to the Effective Time and (ii) the excess, if any, of the Merger Consideration over the per share exercise price of the shares subject to such option award immediately prior to the Effective Time (each a \"Parent Cash-Based Option Award\"). Each Parent Cash-Based Option Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such option award immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based Option Award will vest, subject to the applicable holder's continued employment with Parent through such date. Any outstanding option, whether vested or unvested, to purchase shares of Issuer common stock with an exercise price per share greater than $47.00 was cancelled at the Effective Time for no consideration or payment."}],"balance_after":0,"derivative":{"exercise_price":1.65,"underlying":"Common Stock","underlying_shares":22760},"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1094310,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Share Units","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":579749,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Represents restricted share units subject to performance-based vesting conditions (each, a \"PSU\") granted under the Plan. Each PSU represents a contingent right to receive one share of Issuer common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding PSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such PSU multiplied by (ii) the total number of shares of Issuer common stock subject to any such PSU immediately prior to the Effective Time that vests based on the achievement of performance levels determined in accordance with the applicable PSU award agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":579749},"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1094309,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-07-02T20:18:21.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":954869,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated April 27, 2025 (the \"Merger Agreement\"), by and among the Issuer, Merck KGaA, Darmstadt, Germany, a German corporation with general partners (\"Parent\"), and EMD Holdings Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer effective as of July 1, 2025, with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 162,414 shares underlying restricted stock units (each, an \"RSU\") granted under the Issuer's 2019 Stock Option and Equity Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of Issuer common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding share of Issuer common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding RSU, whether vested or unvested, was cancelled and automatically converted into the right to receive an amount in cash, without interest and subject to any required tax withholding, equal to the product (rounded down to the nearest whole cent) of (i) the Merger Consideration payable with respect to such RSU multiplied by (ii) the total number of shares of Issuer common stock subject to such RSU immediately prior to the Effective Time (each a \"Parent Cash-Based RSU Award\"). Each Parent Cash-Based RSU Award will generally vest in accordance with the vesting terms that applied to the corresponding portion of such RSU immediately prior to the Effective Time; provided, that on the nine-month anniversary of the closing date of the Merger, 50% of each then-unvested tranche of each Parent Cash-Based RSU Award will vest, subject to the applicable holder's continued employment with Parent through such date."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-065298","document":"tm2519678-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925065298/tm2519678-2_4seq1.xml","form_type":"4"}},{"id":1100215,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:18.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018385","document":"form4-06272025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018385/form4-06272025_040608.xml","form_type":"4"}},{"id":1128910,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-05-30T23:28:38.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":201857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":201857,"derivative":{"exercise_price":0.3598,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":201857},"source":{"system":"sec-edgar","filing":"0001415889-25-015056","document":"form4-05302025_110532.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000141588925015056/form4-05302025_110532.xml","form_type":"4"}},{"id":1221708,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:29.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":600,"price":56.89,"value":34134.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."}],"balance_after":954869,"source":{"system":"sec-edgar","filing":"0001104659-25-021005","document":"tm258294-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925021005/tm258294-1_4seq1.xml","form_type":"4"}},{"id":1221707,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:29.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":1400,"price":56.134,"value":78587.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.84 to $56.36. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":955469,"source":{"system":"sec-edgar","filing":"0001104659-25-021005","document":"tm258294-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925021005/tm258294-1_4seq1.xml","form_type":"4"}},{"id":1221706,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:29.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":11600,"price":55.1537,"value":639782.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.70 to $55.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":956869,"source":{"system":"sec-edgar","filing":"0001104659-25-021005","document":"tm258294-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925021005/tm258294-1_4seq1.xml","form_type":"4"}},{"id":1221705,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:29.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":23600,"price":54.243,"value":1280134.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.70 to $54.685. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":968469,"source":{"system":"sec-edgar","filing":"0001104659-25-021005","document":"tm258294-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925021005/tm258294-1_4seq1.xml","form_type":"4"}},{"id":1221704,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:29.000Z","date":"2025-03-03","kind":"sale","planned":true,"acquired":false,"shares":11800,"price":52.9675,"value":625016.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.70 to $53.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":992069,"source":{"system":"sec-edgar","filing":"0001104659-25-021005","document":"tm258294-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925021005/tm258294-1_4seq1.xml","form_type":"4"}},{"id":1221703,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-03-05T23:32:29.000Z","date":"2025-02-27","kind":"tax_withholding","planned":true,"acquired":false,"shares":30756,"price":53.41,"value":1642677.96,"ownership":{"direct":true},"balance_after":1003869,"source":{"system":"sec-edgar","filing":"0001104659-25-021005","document":"tm258294-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925021005/tm258294-1_4seq1.xml","form_type":"4"}},{"id":1248975,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-24T23:58:58.000Z","date":"2025-02-20","kind":"sale","planned":true,"acquired":false,"shares":5068,"price":61.2368,"value":310348.1024,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.93 to $61.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1034625,"source":{"system":"sec-edgar","filing":"0001104659-25-016617","document":"tm257488-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925016617/tm257488-3_4seq1.xml","form_type":"4"}},{"id":1248974,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-24T23:58:58.000Z","date":"2025-02-20","kind":"sale","planned":true,"acquired":false,"shares":24260,"price":60.1011,"value":1458052.686,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.90 to $60.83. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1039693,"source":{"system":"sec-edgar","filing":"0001104659-25-016617","document":"tm257488-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925016617/tm257488-3_4seq1.xml","form_type":"4"}},{"id":1258708,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-19T21:50:33.000Z","date":"2025-02-14","kind":"sale","planned":true,"acquired":false,"shares":10672,"price":59.9222,"value":639489.7184,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.90 to $60.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1063953,"source":{"system":"sec-edgar","filing":"0001104659-25-015218","document":"tm257083-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925015218/tm257083-2_4seq1.xml","form_type":"4"}},{"id":1266693,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-15T00:30:20.000Z","date":"2025-02-12","kind":"tax_withholding","planned":false,"acquired":false,"shares":13186,"price":59.28,"value":781666.08,"ownership":{"direct":true},"balance_after":1074625,"source":{"system":"sec-edgar","filing":"0001104659-25-014376","document":"tm256757-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925014376/tm256757-1_4seq1.xml","form_type":"4"}},{"id":1266692,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-15T00:30:20.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":85309,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents the issuance of performance restricted stock units (\"PSUs\"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's product candidate, GOMEKLI(TM), for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas."},{"field":"security","element":"securityTitle","label":"F2","text":"28,436 PSUs shall vest immediately upon issuance, another 28,436 PSUs shall vest on the date that is 12 months following February 12, 2025 and the remaining 28,437 PSUs shall vest on the date that is the later of (i) 24 months following February 12, 2025 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 28,437 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, \"Measurement Period End Date\" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents the issuance of performance restricted stock units (\"PSUs\"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's product candidate, GOMEKLI(TM), for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas."},{"field":"kind","element":"transactionCoding","label":"F2","text":"28,436 PSUs shall vest immediately upon issuance, another 28,436 PSUs shall vest on the date that is 12 months following February 12, 2025 and the remaining 28,437 PSUs shall vest on the date that is the later of (i) 24 months following February 12, 2025 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 28,437 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, \"Measurement Period End Date\" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan)."}],"balance_after":1087811,"source":{"system":"sec-edgar","filing":"0001104659-25-014376","document":"tm256757-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925014376/tm256757-1_4seq1.xml","form_type":"4"}},{"id":1271116,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-13T00:58:33.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":48000,"price":53.2966,"value":2558236.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1002502,"source":{"system":"sec-edgar","filing":"0001104659-25-012363","document":"tm256428-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925012363/tm256428-3_4seq1.xml","form_type":"4"}},{"id":1303176,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T21:33:41.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":109329,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in forty-eight (48) equal monthly installments following January 10, 2025, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."}],"balance_after":109329,"derivative":{"exercise_price":43,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":109329},"source":{"system":"sec-edgar","filing":"0001104659-25-003463","document":"tm253183-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925003463/tm253183-4_4seq1.xml","form_type":"4"}},{"id":1303175,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-14T21:33:41.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":74834,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 10, 2026, another thirty-three percent (33%) to vest on January 10, 2027 and the remaining thirty-four percent (34%) to vest on January 10, 2028, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."}],"balance_after":1050502,"source":{"system":"sec-edgar","filing":"0001104659-25-003463","document":"tm253183-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925003463/tm253183-4_4seq1.xml","form_type":"4"}},{"id":1307555,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-08T00:13:15.000Z","date":"2025-01-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":12359,"price":38.86,"value":480270.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":975668,"source":{"system":"sec-edgar","filing":"0001104659-25-001770","document":"tm252237-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925001770/tm252237-3_4seq1.xml","form_type":"4"}},{"id":1307554,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-08T00:13:15.000Z","date":"2025-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":12872,"price":38.19,"value":491581.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":988027,"source":{"system":"sec-edgar","filing":"0001104659-25-001770","document":"tm252237-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925001770/tm252237-3_4seq1.xml","form_type":"4"}},{"id":1307553,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-01-08T00:13:15.000Z","date":"2025-01-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":13469,"price":38.19,"value":514381.11,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":1000899,"source":{"system":"sec-edgar","filing":"0001104659-25-001770","document":"tm252237-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465925001770/tm252237-3_4seq1.xml","form_type":"4"}},{"id":1342536,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-04T21:23:24.000Z","date":"2024-12-02","kind":"sale","planned":true,"acquired":false,"shares":3989,"price":41.849,"value":166935.661,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.76 to $42.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1014368,"source":{"system":"sec-edgar","filing":"0001104659-24-125534","document":"tm2430055-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924125534/tm2430055-1_4seq1.xml","form_type":"4"}},{"id":1342535,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-12-04T21:23:24.000Z","date":"2024-12-02","kind":"sale","planned":true,"acquired":false,"shares":45011,"price":41.3326,"value":1860421.6586,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.76 to $41.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1018357,"source":{"system":"sec-edgar","filing":"0001104659-24-125534","document":"tm2430055-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924125534/tm2430055-1_4seq1.xml","form_type":"4"}},{"id":1415217,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-04T20:05:45.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":6692,"price":42.0726,"value":281549.8392,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.58 to $42.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1063368,"source":{"system":"sec-edgar","filing":"0001104659-24-096872","document":"tm2423359-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924096872/tm2423359-2_4seq1.xml","form_type":"4"}},{"id":1415216,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-04T20:05:45.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":9908,"price":41.1041,"value":407259.4228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.52 to $41.505. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1070060,"source":{"system":"sec-edgar","filing":"0001104659-24-096872","document":"tm2423359-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924096872/tm2423359-2_4seq1.xml","form_type":"4"}},{"id":1415215,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-09-04T20:05:45.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":32400,"price":40.0995,"value":1299223.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.52 to $40.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1079968,"source":{"system":"sec-edgar","filing":"0001104659-24-096872","document":"tm2423359-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924096872/tm2423359-2_4seq1.xml","form_type":"4"}},{"id":1470699,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:00:16.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":7.73,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-018013","document":"form4-06242024_050609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924018013/form4-06242024_050609.xml","form_type":"4"}},{"id":1489484,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-05T20:08:37.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":400,"price":42.0925,"value":16837.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.09 to $42.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1112368,"source":{"system":"sec-edgar","filing":"0001104659-24-068675","document":"tm2416457-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924068675/tm2416457-3_4seq1.xml","form_type":"4"}},{"id":1489483,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-05T20:08:37.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":6600,"price":41.401,"value":273246.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.0332 to $42.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1112768,"source":{"system":"sec-edgar","filing":"0001104659-24-068675","document":"tm2416457-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924068675/tm2416457-3_4seq1.xml","form_type":"4"}},{"id":1489482,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-05T20:08:37.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":8760,"price":40.5666,"value":355363.416,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $41.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1119368,"source":{"system":"sec-edgar","filing":"0001104659-24-068675","document":"tm2416457-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924068675/tm2416457-3_4seq1.xml","form_type":"4"}},{"id":1489481,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-06-05T20:08:37.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":33240,"price":39.4003,"value":1309665.972,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on February 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.0147. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Due to an administrative error, the prior Form 4 underreported total ownership by 905,104 shares, but total ownership has been corrected in this Form 4. No reportable transaction was omitted from such filing."}],"balance_after":1128128,"source":{"system":"sec-edgar","filing":"0001104659-24-068675","document":"tm2416457-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924068675/tm2416457-3_4seq1.xml","form_type":"4"}},{"id":1503265,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2024-05-23T20:53:37.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":47693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2025 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":47693,"derivative":{"exercise_price":1.28,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":47693},"source":{"system":"sec-edgar","filing":"0001415889-24-014311","document":"form4-05232024_080531.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000141588924014311/form4-05232024_080531.xml","form_type":"4"}},{"id":1683714,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-09T02:12:30.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in forty-eight (48) equal monthly installments following January 4, 2024, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."}],"balance_after":250000,"derivative":{"exercise_price":38.4,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001104659-24-002379","document":"tm242462-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924002379/tm242462-8_4seq1.xml","form_type":"4"}},{"id":1683713,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-09T02:12:30.000Z","date":"2024-01-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":17904,"price":41.53,"value":743553.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":256264,"source":{"system":"sec-edgar","filing":"0001104659-24-002379","document":"tm242462-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924002379/tm242462-8_4seq1.xml","form_type":"4"}},{"id":1683712,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-09T02:12:30.000Z","date":"2024-01-05","kind":"tax_withholding","planned":false,"acquired":false,"shares":12885,"price":37.96,"value":489114.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs and does not represent a sale by the Reporting Person."}],"balance_after":274168,"source":{"system":"sec-edgar","filing":"0001104659-24-002379","document":"tm242462-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924002379/tm242462-8_4seq1.xml","form_type":"4"}},{"id":1683711,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-01-09T02:12:30.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."},{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty-three percent (33%) to vest on January 4, 2025, another thirty-three percent (33%) to vest on January 4, 2026 and the remaining thirty-four percent (34%) to vest on January 4, 2027, subject to continued service to the Issuer by the Reporting Person through each applicable vesting date."}],"balance_after":287053,"source":{"system":"sec-edgar","filing":"0001104659-24-002379","document":"tm242462-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465924002379/tm242462-8_4seq1.xml","form_type":"4"}},{"id":1725067,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-12-01T21:01:26.000Z","date":"2023-11-30","kind":"grant","planned":false,"acquired":true,"shares":199053,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents the grant of performance restricted stock units (\"PSUs\"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's lead product candidate, Ogsiveo, for the treatment of desmoid tumors."},{"field":"security","element":"securityTitle","label":"F2","text":"66,351 PSUs shall vest on the date that is 15 months following November 30, 2023, another 66,351 PSUs shall vest on the date that is 27 months following November 30, 2023 and the remaining 66,351 PSUs shall vest on the date that is the later of (i) 39 months following November 30, 2023 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 66,351 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, \"Measurement Period End Date\" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents the grant of performance restricted stock units (\"PSUs\"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's lead product candidate, Ogsiveo, for the treatment of desmoid tumors."},{"field":"kind","element":"transactionCoding","label":"F2","text":"66,351 PSUs shall vest on the date that is 15 months following November 30, 2023, another 66,351 PSUs shall vest on the date that is 27 months following November 30, 2023 and the remaining 66,351 PSUs shall vest on the date that is the later of (i) 39 months following November 30, 2023 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 66,351 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, \"Measurement Period End Date\" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan)."}],"balance_after":199053,"source":{"system":"sec-edgar","filing":"0001104659-23-122819","document":"tm2331963-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465923122819/tm2331963-1_4seq1.xml","form_type":"4"}},{"id":1842699,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-29T01:00:13.000Z","date":"2023-06-27","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-040107","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123040107/doc4.xml","form_type":"4"}},{"id":1876008,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-05-26T20:26:18.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of:  (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2024 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":24000,"derivative":{"exercise_price":1,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-23-032546","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000120919123032546/doc4.xml","form_type":"4"}},{"id":2057309,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-10T21:07:24.000Z","date":"2023-01-07","kind":"tax_withholding","acquired":false,"shares":4097,"price":26.41,"value":108201.77,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person."}],"balance_after":905104,"source":{"system":"sec-edgar","filing":"0001104659-23-002717","document":"tm232960-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465923002717/tm232960-6_4seq1.xml","form_type":"4"}},{"id":2058417,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option  (Right to Buy)","published_at":"2023-01-09T22:01:35.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":260000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest in 48 equal monthly installments subject to continued service to the Issuer by the Reporting Person."}],"balance_after":260000,"derivative":{"exercise_price":27.64,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":260000},"source":{"system":"sec-edgar","filing":"0001104659-23-002322","document":"tm232787-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465923002322/tm232787-8_4seq1.xml","form_type":"4"}},{"id":2058416,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-09T22:01:35.000Z","date":"2023-01-06","kind":"tax_withholding","acquired":false,"shares":8400,"price":27.52,"value":231168.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a correction to the total number of securities beneficially owned, previously reported on a Form 4/A filed on January 14, 2022."}],"balance_after":909201,"source":{"system":"sec-edgar","filing":"0001104659-23-002322","document":"tm232787-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465923002322/tm232787-8_4seq1.xml","form_type":"4"}},{"id":2058415,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-01-09T22:01:35.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":84175,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 5, 2024, another thirty three percent (33%) to vest on January 5, 2025 and the remaining thirty four percent (34%) to vest on January 5, 2026, such that the restricted stock awards are fully vested on January 5, 2026."}],"balance_after":917601,"source":{"system":"sec-edgar","filing":"0001104659-23-002322","document":"tm232787-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465923002322/tm232787-8_4seq1.xml","form_type":"4"}},{"id":2234181,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T23:33:56.000Z","date":"2022-06-10","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":18000,"derivative":{"exercise_price":4.18,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001209191-22-036474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122036474/doc4.xml","form_type":"4"}},{"id":2250885,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-05-31T20:25:37.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in full on the earlier of:  (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":24000,"derivative":{"exercise_price":1.76,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-22-032819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000120919122032819/doc4.xml","form_type":"4"}},{"id":2434635,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-14T21:57:47.000Z","date":"2022-01-07","kind":"tax_withholding","acquired":false,"shares":3996,"price":56.06,"value":224015.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person."}],"balance_after":853592,"source":{"system":"sec-edgar","filing":"0001104659-22-004461","document":"tm223052-1_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465922004461/tm223052-1_4aseq1.xml","form_type":"4/A","original_submission_date":"2022-01-11"}},{"id":2437421,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-11T21:02:37.000Z","date":"2022-01-07","kind":"tax_withholding","acquired":false,"shares":5893,"price":56.06,"value":330361.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock awards and does not represent a sale by the Reporting Person."}],"balance_after":851695,"source":{"system":"sec-edgar","filing":"0001104659-22-003143","document":"tm222586d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465922003143/tm222586d2_4.xml","form_type":"4"}},{"id":2438662,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option  (Right to Buy)","published_at":"2022-01-10T21:31:55.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":244258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in 48 equal monthly installments subject to continued service to the company by the Reporting Person."}],"balance_after":244258,"derivative":{"exercise_price":59.46,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":244258},"source":{"system":"sec-edgar","filing":"0001104659-22-002754","document":"tm222382d9_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465922002754/tm222382d9_4.xml","form_type":"4"}},{"id":2438661,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-01-10T21:31:55.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":78370,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction represents a grant of restricted stock units (\"RSUs\"). The RSUs shall vest as follows: thirty three percent (33%) to vest on January 6, 2023, another thirty three percent (33%) to vest on January 6, 2024 and the remaining thirty four percent (34%) to vest on January 6, 2025, such that the restricted stock awards are fully vested on January 6, 2025."}],"balance_after":857588,"source":{"system":"sec-edgar","filing":"0001104659-22-002754","document":"tm222382d9_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465922002754/tm222382d9_4.xml","form_type":"4"}},{"id":2537977,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-20T23:14:10.000Z","date":"2021-10-20","kind":"sale","acquired":false,"shares":10083,"price":58.6658,"value":591527.2614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.65 to $59.195, inclusive."}],"balance_after":779218,"source":{"system":"sec-edgar","filing":"0001104659-21-128168","document":"tm2130713d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921128168/tm2130713d1_4.xml","form_type":"4"}},{"id":2538828,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-19T23:27:03.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":14077,"price":58.8103,"value":827872.5931,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.93 to $59.58, inclusive."}],"balance_after":769135,"source":{"system":"sec-edgar","filing":"0001104659-21-127704","document":"tm2130596-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921127704/tm2130596-1_4seq1.xml","form_type":"4"}},{"id":2538827,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-10-19T23:27:03.000Z","date":"2021-10-18","kind":"sale","acquired":false,"shares":38340,"price":58.5943,"value":2246505.462,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.28 to $60.83, inclusive."}],"balance_after":783212,"source":{"system":"sec-edgar","filing":"0001104659-21-127704","document":"tm2130596-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921127704/tm2130596-1_4seq1.xml","form_type":"4"}},{"id":2563084,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-09-21T21:06:51.000Z","date":"2021-06-04","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest on the earlier of June 4, 2022 or the date of the 2022 annual meeting of the Issuer's stockholders which date has not been set by the Issuer's Board of Directors."}],"balance_after":15000,"derivative":{"exercise_price":28.83,"expiration_date":"2031-06-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-057058","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919121057058/doc4.xml","form_type":"4"}},{"id":2628971,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-07-20T23:34:13.000Z","date":"2021-07-20","kind":"sale","acquired":false,"shares":18572,"price":77.6842,"value":1442750.9624,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $75.90 to $79.23, inclusive."}],"balance_after":821552,"source":{"system":"sec-edgar","filing":"0001104659-21-094094","document":"tm2122747-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921094094/tm2122747-1_4seq1.xml","form_type":"4"}},{"id":2628970,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-07-20T23:34:13.000Z","date":"2021-07-19","kind":"sale","acquired":false,"shares":43928,"price":76.089,"value":3342437.592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $75.05 to $77.38, inclusive."}],"balance_after":840124,"source":{"system":"sec-edgar","filing":"0001104659-21-094094","document":"tm2122747-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921094094/tm2122747-1_4seq1.xml","form_type":"4"}},{"id":2690780,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-28T22:02:57.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":16918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16918,"derivative":{"exercise_price":13.83,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":16918},"source":{"system":"sec-edgar","filing":"0001209191-21-036628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000120919121036628/doc4.xml","form_type":"4"}},{"id":2743819,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-20T22:51:56.000Z","date":"2021-04-20","kind":"sale","acquired":false,"shares":24075,"price":66.3875,"value":1598279.0625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $64.72 to $68.38, inclusive."}],"balance_after":884052,"source":{"system":"sec-edgar","filing":"0001104659-21-052683","document":"tm2113460-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921052683/tm2113460-1_4.xml","form_type":"4"}},{"id":2743818,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-20T22:51:56.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":38425,"price":69.0391,"value":2652827.4175,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $67.37 to $70.84, inclusive."}],"balance_after":908127,"source":{"system":"sec-edgar","filing":"0001104659-21-052683","document":"tm2113460-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921052683/tm2113460-1_4.xml","form_type":"4"}},{"id":2900314,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-21T21:30:51.000Z","date":"2021-01-20","kind":"sale","acquired":false,"shares":2199,"price":78.7541,"value":173180.2659,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $77.83 to $79.24, inclusive."}],"balance_after":1222997,"source":{"system":"sec-edgar","filing":"0001104659-21-006327","document":"tm213781d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921006327/tm213781d1_4seq1.xml","form_type":"4"}},{"id":2900313,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-21T21:30:51.000Z","date":"2021-01-19","kind":"sale","acquired":false,"shares":60301,"price":78.5428,"value":4736209.3828,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $75.46 to $82.59, inclusive."}],"balance_after":1225196,"source":{"system":"sec-edgar","filing":"0001104659-21-006327","document":"tm213781d1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921006327/tm213781d1_4seq1.xml","form_type":"4"}},{"id":2910492,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-11T14:28:53.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest in 48 equal monthly installments subject to continued service to the Company by the Reporting Person."}],"balance_after":300000,"derivative":{"exercise_price":70.68,"expiration_date":"2031-01-07","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001104659-21-002789","document":"tm2022926-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921002789/tm2022926-8_4seq1.xml","form_type":"4"}},{"id":2910491,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-01-11T14:28:53.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awards. The restricted stock awards shall vest as follows: thirty three percent (33%) to vest on January 7, 2022, another thirty three percent (33%) to vest on January 7, 2023 and the remaining thirty four percent (34%) to vest on January 7, 2024, such that the restricted stock awards are fully vested on January 7, 2024."}],"balance_after":1285497,"source":{"system":"sec-edgar","filing":"0001104659-21-002789","document":"tm2022926-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465921002789/tm2022926-8_4seq1.xml","form_type":"4"}},{"id":2955217,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-08T00:53:14.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":69753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020."}],"balance_after":69753,"derivative":{"exercise_price":21,"expiration_date":"2030-12-02","underlying":"Common Stock","underlying_shares":69753},"source":{"system":"sec-edgar","filing":"0001209191-20-062048","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919120062048/doc4.xml","form_type":"4"}},{"id":3226443,"issuer":{"id":15910,"kind":"organization","name":"SpringWorks Therapeutics, Inc.","symbol":"SWTX"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T23:23:01.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in 48 equal monthly installments subject to continued service to the Company by the Reporting Person."}],"balance_after":325000,"derivative":{"exercise_price":33.66,"expiration_date":"2030-03-02","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001104659-20-029346","document":"tm2011556d5_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000110465920029346/tm2011556d5_4.xml","form_type":"4"}},{"id":3230778,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T23:41:52.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":5000,"price":18,"value":90000.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001209191-20-015626","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000120919120015626/doc4.xml","form_type":"4"}},{"id":3237296,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-03-02T22:55:27.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":16918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vest as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":16918,"derivative":{"exercise_price":18,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":16918},"source":{"system":"sec-edgar","filing":"0001209191-20-014697","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1575408/000120919120014697/doc4.xml","form_type":"4"}}]}